Bloodstream-delivered cell therapy slows muscle decline in young people with Duchenne muscular dystrophy, trial finds

A cell therapy called deramiocel could slow muscle weakening in boys and young men with advanced Duchenne muscular dystrophy (DMD) and may also slow heart damage in those who already have heart muscle disease, a Phase III clinical trial published in The Lancet has found.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup